Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7529.09 | 0.3359 | -0.8193 | 0.4538 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7529.09 | 0.9340 | 0.7207 | 0.4538 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 9044.091 | 1.0148 | 1.0462 | 0.6432 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 9044.091 | 1.0306 | 1.0958 | 0.6432 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 9044.091 | 1.0716 | 1.2272 | 0.6432 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 9044.091 | 1.1232 | 1.3959 | 0.6432 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 9044.091 | 1.1361 | 1.4389 | 0.6432 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 9044.091 | 1.0776 | 1.2465 | 0.6432 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 9044.091 | 0.8179 | 0.4633 | 0.6432 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 9044.091 | 0.0217 | -0.9948 | 0.6432 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 9044.091 | 0.0079 | -0.9989 | 0.6432 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 10381.092 | 0.9273 | 0.8960 | 1.4137 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 10381.092 | 0.9970 | 0.9958 | 1.4137 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 10381.092 | 0.9653 | 0.9506 | 1.4137 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 10381.092 | 1.0445 | 1.0625 | 1.4137 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 10381.092 | 1.0984 | 1.1373 | 1.4137 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 10381.092 | 1.0630 | 1.0883 | 1.4137 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 10381.092 | 0.7334 | 0.6061 | 1.4137 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 10381.092 | 0.0291 | -0.8363 | 1.4137 | |
| SUM1315MO2 | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 10381.092 | 0.0082 | -0.9329 | 1.4137 | |
| SUM149PT | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7530.091 | 0.9586 | 0.9597 | 2.0794 | |
| SUM149PT | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7530.091 | 1.0246 | 1.0235 | 2.0794 | |
| SUM149PT | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7530.091 | 0.9834 | 0.9840 | 2.0794 | |
| SUM149PT | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7530.091 | 1.0582 | 1.0551 | 2.0794 | |
| SUM149PT | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7530.091 | 1.0776 | 1.0732 | 2.0794 |